Inpharma 1570 - 13 Jan 2007

1

■ Levofloxacin is efficacious in the treatment of children with, or at high risk for, recurrent or persistent acute otitis media, reports a multinational group of researchers. In their open-label study, 204 such patients aged ≥ 6 months and < 5 years received oral levofloxacin 10 mg/kg/day, with a maximum daily dose of 500mg, for 10 days.* Of the 89 patients who had a causative pathogen isolated from their middle-ear fluid at baseline, 78 achieved documented or presumed bacterial eradication from middle-ear fluid at 4–6 days of levofloxacin therapy. Clinical success, defined as a partial or complete resolution of signs and symptoms, was achieved in 135 of 144 evaluable patients at 2–5 days after completing treatment. * This study was supported by Johnson & Johnson Pharmaceutical Research and Development, US. Arguedas A, et al. An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media. Pediatric Infectious Disease Journal 25: 1102-1109, No. 12, 801059574 Dec 2006

1173-8324/10/1570-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Inpharma 13 Jan 2007 No. 1570